We have modified the pCL retroviral system by the insertion of a p53-responsive element, called PG, in the U3 region of the 3V-LTR, either in addition to or in place of the native negative control region/enhancer sequence. We show here that either endogenous or exogenous wild-type p53 may be used to drive expression from the pCLPG system in transduced cells. Upon genotoxic induction of endogenous p53, pCLPG expression surpassed that of the parental, nonmodified virus, specifically when the native promoter was removed and substituted by the p53-responsive element. We propose that the novel pCLPG system will prove to be a valuable tool whether used as a reporter system of p53 function or as an in vitro and in vivo gene transfer vehicle. D
Introduction
For increased efficacy and safety, tight transcriptional control is a highly desirable feature in a viral gene transfer vector. We have chosen to employ wild-type p53 as a transcriptional activator of retroviral expression because p53 activity is inducible and, in the active state, is a robust transcription factor (Ko and Prives, 1996) . The activity of the wild-type p53 protein includes transcriptional activation of key cell-cycle and pro-apoptotic control genes, for example, p21Waf1 (el-Deiry et al., 1993) and the p53 antagonist, mdm2 (Barak et al., 1993; Haupt et al., 1997) . Transcriptional activation by p53 is mediated via direct binding to a known DNA motif present in the regulatory elements of target genes (el-Deiry et al., 1993; Funk et al., 1992) . P53 also suppresses expression from a variety of promoters, including anti-apoptotic control genes (Miyashita et al., 1994a (Miyashita et al., , 1994b , the multidrug resistance gene (Chin et al., 1992; Strauss et al., 1995) , and some viral promoters, including the LTRs of RSV, HIV-I, and HTLV-1 (Subler et al., 1992) . One of the first p53-responsive elements to be identified was isolated from the ribosomal gene cluster (RGC) (Kern et al., 1991) . In the PG13-CAT reporter construct, 13 copies of the RGC element were joined to a minimal promoter and the chloramphenicol acetyltransferase (CAT) cDNA, resulting in a highly sensitive p53-responsive regulatory unit (Kern et al., 1992) . In this study, we have altered retroviral expression by inserting the PG element into the U3 region of the 3V-LTR of the Moloney Murine Leukemia Virus-based (MoMLV) pCL retrovirus with the hope of gaining high-level expression driven by p53 in infected cells. This method was preferred over the insertion of p53-responsive promoters, such as for the p21Waf1 gene, because these promoters may also act in a p53-independent fashion (Michieli et al., 1994; Seoane et al., 2002) . We present here cell culture-based assays to establish the function of the newly constructed pCLPG retroviral gene transfer system.
Results

Construction and production of modified pCL virus
In order to generate retroviruses with p53-driven expression, the PG element was isolated (Kern et al., 1992) and inserted in the U3 region of the 3V-LTR of the MoMLV-based pCL retrovirus (Naviaux et al., 1996) maintaining the native enhancer elements (pCLPG+, pCLPGÀ, Fig. 1 ) where the PG element was placed in either the sense (+) or antisense (À) orientation. Alternatively, the enhancer and negative control regions were deleted and replaced by the PG element (pCLPG+DU3, pCLPGÀDU3, Fig. 1 ) where the PG element was placed in either the sense (+) or antisense (À) orientation. These four arrangements were tested with the intention Fig. 1 . Maps of the pCLPG system and p53-dependent expression after acute infection of the pCLPG system followed by transfection with p53 expression vectors. (A) The original MoMLV-derived pCL system (Naviaux et al., 1996) was modified by the insertion of 13 copies of a p53-responsive element derived from the PG13-CAT reporter construct (Kern et al., 1992) . The sequence is referred to here as the PG element. The nonmodified vector, pCL, is shown with detail of the CMV-R-U5 fusion at the 5V-LTR, the presence of the packaging signal, the multiple cloning site, the SV40 promoter that drives expression of the neomycin resistance gene (Neo R ), and the 3V-LTR with the negative control region (N), enhancer elements (E), and NheI and XbaI restriction sites indicated. For the pCLPG vectors, the PG element was inserted in the XbaI site, maintaining the N and E sequences, as detailed in the diagram, and clones were isolated with the PG element in both orientations (pCLPG+ and pCLPGÀ). For the pCLPGDU3 vectors, the PG element was inserted in the NheI and XbaI sites, replacing the N and E sequences, as detailed in the diagram, and clones were isolated with the PG element in both orientations (pCLPG+DU3, pCLPGÀDU3). The native CAT and TATA elements were maintained in all of the modified constructs. The chloramphenicol acetyltransferase (CAT) cDNA was inserted into the multiple cloning sequence of each of the four modified vectors as well as the nonmodified parental construct. For simplicity, the vectors are referred to here as the pCLPGCAT series (pCL, pCLCAT, pCLPG+CAT, pCLPGÀCAT, pCLPG+DU3CAT, pCLPGÀDU3CAT) . (B) The 293 cell line (endogenous wild-type p53 inactivated by adenovirus E1B protein) was infected at an MOI of 0.6 with each one of the six viruses in the pCLPGCAT series (as indicated in the figure) in a 6-cm dish, the day the infected cells were equally divided between three fresh 6-cm dishes, transfected the following day with 5 Ag of an empty CMV vector (V), or the CMV vector encoding wild-type p53 (p53wt) or mutant p53 (p53mut). After an additional 24-h incubation, the infected and transfected cells were harvested for CAT assays. Each assay was performed with 30 Ag of protein lysate for 60 min. The histogram depicts the mean F standard deviation of three independent experiments. of achieving maximum viral expression driven by p53. The cDNA for chloramphenicol acetyltransferase (CAT) was inserted in the modified vectors as well as the nonmodified pCL vector to serve as a control. A similar range of viral titers, as determined by G418 resistance in an endpoint dilution assay, was obtained for the parental vectors, pCL and pCLCAT (3 Â 10 6 , 2 Â 10 5 , respectively), and the modified pCLPG+CAT, pCLPGÀCAT, pCLPGD+CAT, or pCLPGDÀCAT constructs (1 Â 10 5 , 6 Â 10 5 , 2 Â 10 5 , 8 Â 10 6 cfu/ml, respectively). Assessment of replication competent virus showed no additional generation of recombinant virus for the PG-modified vectors as compared to the parental, nonmodified vector (data not shown). These results indicate that the modifications were not harmful to the processes of virus production, infection, or selection.
Expression of the pCLPG system in an acute infection assay
To begin testing of the pCLPG system, 293 cells were infected at an equal multiplicity of infection with pCL, pCLCAT, pCLPG+CAT, pCLPGÀCAT, pCLPG+DU3CAT, or pCLPGÀDU3CAT (for simplicity referred to as the pCLPGCAT series), replated the following day, and then transfected with CMV-driven expression vectors for wildtype or mutant p53. As seen in Fig. 1B , the introduction of the p53 expression vectors had only a minimal effect on the expression of the nonmodified pCLCAT virus. In contrast, all PG-modified viruses exhibited an increase in viral expression in the presence of wild-type p53, but not in the presence of the empty or mutant p53 vectors. This indicates that the pCLPG system is indeed activated by p53 in acutely infected cells. The expression observed from the pCLPGÀDU3CAT vector in the presence of exogenous p53 was greater than that of the nonmodified pCLCAT virus.
Assessment of basal expression in a variety of cell types
The expression of the pCLPG system was consistent with the phenotype of the endogenous p53 in several cell lines. The human lung carcinoma cell line H358 (p53-null), the human glioblastoma cell lines U251 (mutant p53) and U87 (wild-type p53), as well as the human osteosarcoma Saos-2 (p53À/À) cell line were each infected with the pCLPGCAT series (MOI < 1), selected for G418 resistance, and assayed for viral expression. As seen in Fig. 2 , the expression from the parental pCL virus was quite variable and appeared to be quite low in Saos-2 cells, yet was greater in the other lines when reactions were performed under similar conditions. The lack of endogenous p53 in the H358 cells corresponded with negligible expression from the pCLPG system. In the U251 cells, the activity of the pCLPG system was quite reduced as compared to the parental virus, presumably because of the lack of functional p53. The endogenous, wild-type p53 in the U87 cells appeared to activate the PGmodified viruses, though expression was less than that from the parental virus. Expression from the pCLPG+CAT, pCLPGÀCAT, and pCLPG+DU3CAT viruses was barely detectable in the p53-null Saos-2 cells, yet leaky expression from the pCLPGÀDU3CAT virus was observed. These assays indicate that the basal expression from the pCLPG system is quite low in the absence of p53.
Expression from the pCLPG system in response to a temperature-sensitive mutant of p53
Next, we wished to compare the basal and induced expression from the pCLPG system when p53 was provided stably by an expression vector. A temperature-sensitive mutant of murine p53 (Michalovitz et al., 1990) was introduced into the Saos-2 (p53À/À) human osteosarcoma cell line previously transduced with the pCLPGCAT series of viruses, as described above, via a second retroviral infection using the pBabep53(Val135)puro retrovirus. These cells were then selected for puromycin resistance with continued presence of G418 in the culture media. Batchselected cells were then cultured at either 37 jC, where p53 adopts a mutant conformation and is unable to activate transcription, or at 32 jC, where p53 assumes wild-type conformation and activity. Cells were collected after 5 days of temperature conditioning and analyzed for reporter gene activity.
Measurement of viral expression with the CAT reporter gene in the temperature-sensitive system revealed p53-specific expression that surpassed the level of expression seen in the parental virus (Figs. 2B, C) . In the absence of p53, negligible background expression was observed from the pCLPG+CAT or pCLPGÀCAT vectors, yet leaky expression was evident for the pCLPGÀDU3CAT vector at both 32 and 37 jC, and the pCLPG+DU3CAT vector revealed background expression only at 32 jC. The nonspecific band present in these assays migrated differently than either the mono-or diacetylated forms of chloramphenicol, and was discounted from the densitometric analyses. In the presence of mutant p53, at 37 jC, the SaospCLPGCAT/p53(Val135) series of cell lines exhibited only background expression, equal to that in the complete absence of p53. Strikingly, the PG-modified vectors were induced at 32 jC in the presence of wild-type p53 activity. Expression from the pCLPGÀDU3CAT vector was measured to be nearly sevenfold greater than the nonmodified parental pCLCAT vector.
Endogenous p53 can be induced to drive expression of the pCLPG system
To demonstrate the p53-inducible nature of the pCLPG system, NIH3T3 cells (p53+/+) were infected with the pCLPGCAT series of viruses (MOI < 1) and selected for G418 resistance. Cells were treated with 100 ng/ml doxorubicin, a genotoxic and p53-inducing chemotherapeutic drug, and cell lysates were harvested and tested for CAT expression. As seen in Fig. 3A , expression from the pCLCAT parental virus was readily detectable in the absence of drug treatment, but decreased slightly with the addition of doxorubicin. In contrast, the expression of the reporter gene from each of the PG-modified viruses increased with drug treatment, as much as threefold for pCLPG+DU3CAT. Notably, when in the presence of doxorubicin, expression from the pCLPGÀDU3CAT virus was nearly twofold greater than that of the nonmodified pCLCAT virus. The pCLPGÀDU3 arrangement conferred a p53-inducible expression that surpassed that of the parental, nonmodified virus, corroborating the results seen in Figs. 1 and 2 .
To explore the p53-responsive nature of the pCLPG system at the transcriptional level, a Northern blot was performed using total RNA isolated from the NIH3T3 cells infected with the pCLPGCAT series, with and without doxorubicin treatment. As seen in Fig. 3B , expression from the pCLCAT vector was diminished slightly by drug treatment as indicated by detection of the viral transcript with either the CAT or Neo R cDNA probes. In contrast, all PGmodified vectors were induced by drug treatment.
To relate the above results with the physiologic response of the endogenous p53 to drug treatment, Western blots and RT-PCR were performed using either protein lysates or total RNA, respectively, of the NIH3T3-pCLPGCAT series of cell lines. As shown in the Western blot (Fig. 3C) , the level of endogenous p53 protein is quite low in the absence of drug treatment, yet exposure to doxorubicin induced the stability of the p53 protein. The stabilized p53 protein is known to activate the expression of a variety of genes, including p21Waf1. Indeed, expression of this p53-target gene was activated in response to drug treatment, in agree- The H358 (human lung carcinoma, p53À/À), U251 (human glioblastoma, mutant p53), and U87 (human glioblastoma, wild-type p53) cell lines were infected with the pCLPGCAT series of vectors, selected for G418 resistance and cell lysates analyzed by CAT assays. For these assays, an equal amount of protein was applied for each cell line (2 -30 Ag), however the quantity for each line of origin was adjusted to maintain assays within the linear range. The histograms show the mean percent of the chloramphenicol substrate converted to the acetylated form in at least three independent experiments. Lane designations described below. (B) Saos-2 cells (p53À/À human osteosarcoma) infected with the pCLPGCAT series of virus and selected for G418 resistance were reinfected with the pBabep53(135)puro virus and selected for puromycin resistance while in the continued presence of G418, resulting in the generation of the Saos-pCLPGCAT and Saos-pCLPGCAT/p53(135) series of cell lines. CAT activity measured after induction of the pCLPG system by this temperature-sensitive mutant of p53. The Saos-pCLPGCAT series of cell lines was incubated at 32 jC (white bars) or 37 jC (striped bars) and the Saos-pCLPGCAT/p53(135) series of cell lines was incubated at 32 jC (black bars) or 37 jC (stippled bars) for 120 h before harvesting of cells and analysis of CAT activity. The histogram represents the mean percentage of conversion of chloramphenicol to the acetylated form, as determined by densitometric analysis of the autoradiographs, from two independent experiments. Lane designations described below. (C) Representative examples of the CAT assays described in panel B. Note the presence of a nonspecific background band; this band was discounted from the densitometric measurements. For (A), (B), and (C), lanes were 1, pCL; 2, pCLCAT; 3, pCLPG+CAT; 4, pCLPGÀCAT; 5, pCLPG+DU3CAT; and 6, pCLPGÀDU3CAT. ment with well-defined p53 functions. The semiquantitative RT-PCR assay (Fig. 3D) confirmed this widely-known mechanism, showing that p53 RNA was not elevated in response to drug treatment, yet the p53-target genes p21Waf1 and mdm2 were. Taken together, these results indicate that the drug treatment induced p53 activity which, in turn, induced expression from the pCLPG system.
Discussion
We have constructed the pCLPG retroviral gene transfer system whose expression is driven by p53. In the pCLPGinfected cell, LTR-driven expression depends principally on wild-type p53 activity. This was shown by the introduction of p53 in infected cells as well as by the induction of endo- Fig. 3 . Activation of endogenous p53 by a genotoxic drug induces expression from the pCLPG system. NIH3T3 cells (wild-type p53) were infected (MOI < 1) with the pCLPGCAT series of viruses and selected for G418 resistance. For these assays, 0 or 100 ng/ml doxorubicin was added and the cells incubated 24 h before harvesting for CAT assays, Northern or Western blots. (A) CAT assay were performed with an equal quantity of protein from each lysate, 5 Ag, and incubated for 30 min at 37 jC. The histogram represents the mean F standard deviation of densitometric analyses of two independent experiments. Lane designations described below. (B) Northern blot analysis of total RNA probed sequentially with the CAT, Neo R , or h-actin cDNAs. A single membrane was used for this experiment, exposures made to phosphor imaging screen, and stripped between probes. Note the altered migration of transcripts hybridizing with CAT or NeoR cDNAs that represents the expected alteration in transcript length due to the inserted cDNA and alteration to the LTR. For (A) and (B), lanes were 1, pCL; 2, pCLCAT; 3, pCLPG+CAT; 4, pCLPGÀCAT; 5, pCLPG+DU3CAT; and 6, pCLPGÀDU3CAT. (C) Western blot analysis of endogenous p53 and its transcriptional target, p21Waf1, after treatment with doxorubicin. For the Western blot, an immunoprecipitation was first performed using the indicated antibody, then the complex analyzed by Western blot using the same antibody. This procedure served to concentrate the target protein. The same lysate was subjected to the immunoprecipitation-Western analysis sequentially with each antibody. Detection of h-actin protein serves as a control for sample handling and loading. (D) Semiquantitative RT-PCR for the analysis of the transcripts of p53 and its target genes p21Waf1 and mdm2 with or without drug treatment. For the RT-PCR, negative controls (water in PCR, lane 1, water in RT, lane 2), h-actin (lanes 3, 4), p53 (lanes 5, 6), p21Waf1 (lanes 7, 8), and mdm2 (lanes 9, 10) were amplified as described in the Materials and methods. The result from NIH3T3-pCL is shown here; the remaining lines in the NIH3T3-pCLPGCAT series yielded the same result and, therefore, are not shown. genous p53 activity in NIH3T3. In addition, the pCLPG system was tested in a variety of different cell types after infection and selection, revealing variable activity of the nonmodified LTR as well as expression driven by the PG modified LTR in a p53-associated manner. Strikingly, expression from the pCLPG system could surpass that of the parental, nonmodified virus by up to sevenfold.
We propose that the new virus system will prove to be a valuable tool for either gene transfer or reporter assays. For studies of gene transfer, the replacement of the negative control region and enhancer element may prove beneficial for long-term expression in vivo (Challita et al., 1995) . The responsiveness of the pCLPG system to p53 may be utilized to restrict expression to p53-positive cells and further induce expression when those cells are treated with a genotoxic drug, as was clearly demonstrated with the pCLPGÀDU3 vector whose expression surpassed that of the parental pCL virus. Retroviral transduction of hematopoietic stem cells with MDR1 (Chin et al., 1993) has been extensively studied and attempted clinically, but with disappointing results because of both the lack of expression of the transgene and poor transduction efficiency (Hanania et al., 1996; Hesdorffer et al., 1998) . In the case of pCLPG-mediated delivery of the MDR1 cDNA, a drug used for chemotherapy and which activates p53 should, in turn, activate MDR1 expression in the hematopoietic cells, protecting and selecting them for continued proliferation.
The pCLPG system may be utilized as a reporter construct, especially the pCLPG+ vector that yielded the lowed background expression of the LTR modifications tested. Applied to monitor p53 activity in vivo, the target tissue may be infected by the pCLPG virus system, or ex vivo, because cells may be removed, infected, and then implanted in a recipient. The ex vivo approach may be especially interesting to monitor p53 activity in the hematopoietic system during reconstitution, upon genotoxic stress, or upon immunologic activation.
Materials and methods
Parental vectors
The MoMLV-based pCL and pCL-amphotropic packaging vectors are described in Naviaux et al. (1996) .
Construction of the pCLPG system
The PG element (13 copies of the p53 responsive element) (Kern et al., 1992) was gel isolated from the PG13-CAT construct following digestion with HindIII and SmaI and a fill-in reaction to render the HindIII overhang ''blunt''. The pCL retroviral vector (Fig. 1) was cut with XbaI and the overhangs were filled in to produce blunt ends. The PG element was then ligated into the pCL vector. Clones were isolated where the PG element was situated in the positive orientation (pCLPG+) or in the negative orientation (pCLPGÀ) as shown in Fig. 1 .
Alternatively, the pCL vector was cut with NheI and XbaI, treated with T4 DNA polymerase to create blunt ends, and the 7.3 kb vector fragment was gel isolated before insertion of the PG element. The resulting clones have the endogenous pCL enhancer elements deleted and replaced with the PG element. Clones were isolated where the PG element was situated in the positive orientation (pCLPG+ DU3) or in the negative orientation (pCLPGÀDU3) as shown in Fig. 1 .
Construction of the pCLPGCAT series
The CAT cDNA was isolated as an 800 bp HindIII fragment from the pBS-IRES-CAT vector (Patricia Léo, University of São Paulo, São Paulo, Brazil, derived from the pLZIC2 vector, Ghattas et al., 1991 , kindly provided by John Majors, Washington University, St. Louis, MO, USA) and inserted into the HindIII site of pBluescript to create pBS-CAT. The CAT cDNA was then excised as an 800 bp BamHI fragment and inserted into the BamHI site of pCL, pCLPG+, pCLPGÀ, pCLPG+DU3, and pCLPGÀDU3 to create the pCLCAT, pCLPG+CAT, pCLPGÀCAT, pCLPG+DU3CAT, and pCLPGÀDU3CAT vectors.
Cell culture and lines
The adenovirus-transformed, human embryo kidney cell line 293T (DuBridge et al., 1987) , the p53-null, human lung carcinoma cell line H358 (ATCC: CRL-5807), the p53-null, human osteosarcoma cell line Saos-2 (ATCC: HTB-85), the mouse fibroblast NIH3T3 (ATCC: CCL-163), the human glioblastoma cell lines U87 (ATCC HTB-14), and U251 were maintained in DMEM (Gibco-BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, HyClone, Logan, UT, USA), 100 Ag/ml gentamycin, 50 Ag/ ml ampicillin, and 2.5 Ag/ml fungizone, at 37 jC, in a humidified atmosphere of 5% CO 2 . H358, Saos-2, NIHT3, U87, and U251 cells were infected (MOI < 1) with the pCL or pCLPGCAT series of viruses and selected with 800 Ag/ml G418 (Invitrogen Life Technologies, Carlsbad, CA, USA), then maintained as batch-selected cells with 400 Ag/ml G418 in DMEM, creating the five pCLPGCAT series of cell lines. For the Saos-pCLPGCAT series of cell lines, a second infection was performed with the pBabep53(135)-puro virus supernatant (see following sections) and cells were selected with 0.5 Ag/ml puromycin (Sigma, USA) in the presence of 400 Ag/ml G418 in complete medium, creating the Saos-pCLPGCAT/p53(135) series of cell lines.
Virus production, titration, and RCR assay
To produce virus-containing supernatant, the indicated viral and amphotropic packaging vectors were transfected in the 293 cells as described (Bajgelman et al., 2003; Naviaux et al., 1996) . After 24 h of incubation, the virus-containing supernatant was collected, centrifuged for 5 min, 1000 rpm, then the supernatant removed and stored at À70 jC. The pBabep53(Val135)puro retroviral vector was kindly provided by Moshe Oren, Weizmann Institute, Rehovot, Israel. This vector encodes the mouse temperature-sensitive allele of p53 (Michalovitz et al., 1990) as well as the puromycin resistance gene. Viral supernatant was produced as per the pCL-based vectors co-transfecting the pCL-Ampho packaging construct along with pBabep53(Val135)puro. Titration, performed by end-point dilution and selection for G418 resistance, and the assay for replication competent retrovirus (RCR) were performed as described previously (Bajgelman et al., 2003) .
CAT assays
CAT assays (Gorman et al., 1982) were performed using 5 -150 Ag of lysate, 1 Al of 14C-chloramphenicol (CFA515, Amersham-Pharmacia), 2 Al of 10 mg/ml acetyl Co-A, and 250 mM Tris, pH 7.8, to a final volume of 125 Al. The reactions were incubated at 37 jC for 1-2 h before extraction with 500 Al of ethyl acetate. The organic layer was transferred to a fresh tube and dried under vacuum. The pellet was then resuspended in 25 Al of ethyl acetate and applied to a silica gel thin-layer chromatography plate. The plate was then placed in a TLC chamber equilibrated with 100 ml of 93:7 chloroform and methanol, respectively, and migration of the solvent front was allowed to proceed until reaching the end of the plate. The plate was then removed, dried, and exposed to X-ray film overnight. Quantification was performed by densitometry.
Northern blot for the detection of p53, neomycin-resistance gene, and b-actin For the NIH3T3-pCLPGCAT series, one 10-cm dish of each cell line were treated overnight with complete medium, and 100 ng/ml of doxorubicin and an additional dish was incubated in parallel, with no drug treatment, and all lines were maintained at 37 jC before purification of total RNA using Trizol reagent (Invitrogen Life Technologies) according to the manufacturer's instructions. The RNA, 20 Ag of each sample, was separated by denaturing gel electrophoresis, transferred to HyBond nylon membrane (Amersham Biosciences), and subjected to UV-cross-linking. The membrane was then probed using 32P-dCTP-labeled cDNAs for CAT (800 bp BamHI fragment recovered from pCLCAT), h-actin (2.0 kb fragment provided by Rui Curi, ICB-USP), and the neomycin resistance gene (800 bp HindIII -NaeI fragment recovered from pCL) using Rapid-Hyb solution and protocol (Amersham Biosciences). The membrane was stripped by boiling in 0.1Â SSC/0.1% SDS between each probe and after exposure to phosphor imaging screen.
Western blot for the detection of p53, p21Waf1 and b-actin Western blots for the NIH3T3-pCLPGCAT series were performed, where a sub-confluent 10-cm dish of each cell line was treated overnight with complete medium and 100 ng/ml of doxorubicin and an additional dish incubated in parallel, with no drug treatment, and all lines were maintained at 37 jC. The cells were lysed in 1 ml of lysis buffer (1Â PBS, 1% NP-40, 0.1% SDS, 200 U/ml aprotinin, 0.5 mM PMSF, and 0.1 mM EDTA). An immunoprecipitation was performed with a p53-specific antibody (PAb 421, Oncogene Research Products, USA) and the complex was separated by SDS-PAGE and detected by Western blot. The same lysate was then sequentially analyzed with p21Waf1 (Santa Cruz Biotechnologies, CA, USA) and then h-actinspecific (Sigma-Aldrich, St. Louis, MO, USA) antibodies by the same immunoprecipitation-Western procedure.
Semiquantitative RT-PCR
For the NIH3T3-pCLPGCAT series of cell lines, a subconfluent 10-cm dish of each cell line was treated overnight with complete medium and 100 ng/ml of doxorubicin and an additional dish incubated in parallel, with no drug treatment, and all lines were maintained at 37 jC. Total RNA was isolated with Trizol reagent (Invitrogen Life Technologies) and resuspended in DEPC-treated water. Equal amounts of total RNA were used as the template in reverse transcriptase reactions (2 Ag total RNA, 250 ng random hexamers, 1 Al of 10 mM dNTPs, DEPC-treated water to 12 Al, then heated before the addition of 4 Al 5Â buffer, 2 Al of 0.1 M DTT, 200 units MMLV reverse transcriptase [Invitrogen Life Technologies], incubated 37 jC for 60 min). The RT reactions were diluted 1:1 with water, then 1 Al used in each PCR reaction (50 pmol each primer, 1 Al 10 mM dNTPs, 1 Al 50 mM MgCl 2 , 2.5 Al 10Â buffer, 2.5 units Platinum Taq [Invitrogen Life Technologies] and water to 25 Al) and cycled as follows: 95 jC, 3 min, 25 cycles of 95 jC, 1 min, 57 jC, 1 min, 72 jC, 1 min, h-Actin 5V-gcaagagaggtatcctgacc-3V 5V-ctctttgatgtcacgcacga-3V M12481 464 p53 5V-ggagtcacagtcggatatca-3V 5V-accagctggcagaatagctt-3V NM011640 399 p21 5V-actttgacttcgtcacggag-3V 5V-aagaccaatctgcgcttgga-3V AF457188 314 mdm2 5V-ggccaatgtgcaataccaac-3V 5V-ggactccaaacacatctcct-3V X58876 260
followed by a 5-min incubation at 72 jC. The oligonucleotide primers, presented in Table 1 , were based on mouse gene sequences and were designed to specifically amplify cDNA. The reactions were separated by electrophoresis in 1.3% agarose and photographed and analyzed with an EagleEye Imaging system (Stratagene, La Jolla, CA, USA).
